Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135429 | 1.00 | NEU2 (0.43) | NEU2 | |
| SCHEMBL23085431 | 1.00 | NEU2 (0.43) | NEU2 | |
| SCHEMBL14396716 | 1.00 | NEU2 (0.43) | NEU2 | |
| SCHEMBL99310 | 0.91 | — | — | |
| SCHEMBL99311 | 0.91 | — | — | |
| SCHEMBL14435656 | 0.91 | — | — | |
| SCHEMBL23085258 | 0.88 | NEU2 (0.37) | NEU2 | |
| SCHEMBL23662962 | 0.88 | NEU2 (0.37) | NEU2 | |
| SCHEMBL99320 | 0.85 | NEU2 (0.40) | NEU2 | |
| SCHEMBL99326 | 0.85 | NEU2 (0.40) | NEU2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | CIDARA THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-22 | — | — | US | disclosed |
| EP-2576553-A2 | HIGHLY SELECTIVE ASYMMETRIC HYDROFORMYLATION OF (1S,4R) OR (1R,4S)-2-AZABICYCLO[2.2.1]HEPT-5-EN-3- ONE (+) OR (-)-LACTAM | Dr. Reddy's Laboratories Ltd. (IN) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011150205-A2 | HIGHLY SELECTIVE ASYMMETRIC HYDROFORMYLATION OF (1S,4R) OR (1R,4S)-2-AZABICYCLO[2.2.1]HEPT-5-EN-3- ONE (+) OR (-)-LACTAM | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398226-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | NEU2 12/4885 |
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | NEU2 12/4885 |
| US-11833213-B2 | Compositions and methods for the treatment of viral infections | FCGR3B, ALB, FCGR1A | NEU2 12/4885 |
| US-20210220478-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | NEU2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.